Literature DB >> 22269779

IgG4-related skin disease, a mimic of angiolymphoid hyperplasia with eosinophilia.

Yasuhito Hamaguchi1, Manabu Fujimoto, Yukiyo Matsushita, Seiko Kitamura-Sawada, Mitsuhiro Kawano, Kazuhiko Takehara.   

Abstract

Mikulicz's disease is considered one of the IgG4-related diseases that are characterized by elevated serum IgG4 concentrations and the immunohistochemical finding of IgG4-positive plasma cells. The IgG4-related diseases often exhibit a wide variety of eosinophil infiltration. A 66-year-old male with Mikulicz's disease developed multiple, nonpruritic, red papules on the left opisthotic region 2 years after diagnosis. A biopsy of the skin lesions revealed follicle-like formation in the dermis and subcutaneous tissue containing nodular lymphocytic infiltration with numerous eosinophils and plasma cells, predominately around venules, mimicking angiolymphoid hyperplasia with eosinophilia (ALHE). Immunohistochemically, most IgG-expressing plasma cells were positive for IgG4 (IgG4/IgG ratio = 72%). Our patient appeared to have a condition associated with the IgG4-related diseases. Caution should be exercised in diagnosing skin lesions of the IgG4-related diseases, which are confusingly similar in appearance and histology to ALHE.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22269779     DOI: 10.1159/000335372

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  2 in total

1.  Angiolymphoid Hyperplasia with Eosinophilia with Clinical Presentation Concerning for Juvenile Temporal Arteritis.

Authors:  Emily Li; John Sinard; Alberto Distefano; Mahsa Sohrab
Journal:  Ocul Oncol Pathol       Date:  2019-06-28

2.  Angiolymphoid hyperplasia with eosinophilia in the lungs: a complex name for an innocuous disease?

Authors:  Cátia Alexandra Correia Pereira; Filipa Mendes Ferro; Ana Filipa Dos Santos Matos; Mariana Denise Lourenço Graça Antunes; Pierpaolo Cusati
Journal:  J Bras Pneumol       Date:  2020-04-22       Impact factor: 2.624

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.